OVERVIEW
GOMEZ Emmanuel
SQUEDIN Thomas
LETURGEZ Thibaut
DELEPIERRE Alban
Institut Mérieux
• Silliker, headquartered in Chicago;
• Institut Mérieux has a 89% holding in the
company;
• Within the Nutrition / Health division of
Institut Mérieux, Silliker’s mission is both to
improve nutrition and enhance the quality
and safety of food products.
• Transgene, based in Strasbourg;
• Biopharmaceutical company dedicated to
treating infectious diseases and cancer.
• Institut Mérieux has a 55% holding in the
company;
• It develops therapeutic vaccines and innovative
immunotherapy products based on exclusive
technologies for stimulating patient immune
systems by using vectors for the expression of
tumoral or infectious antigens in target cells.
BioMérieux : Presentation
 A world leader in the field of in vitro diagnostics for over
45 years.
• Designs, develops, manufactures and markets
Reagents,
Automated instruments.
• For medical analysis and quality control of products of
agro-food, cosmetics and pharmaceuticals.
 Contribute to the improvement of public health
worldwide
History
• Marcel Mérieux creates the Institute Mérieux, which developed a large
range of vaccin and biological products.
1897
• Creation of BD Mérieux equally owned by Institute Mérieux and Becton
Dickinson.
1963
• Alain Mérieux takes majority control of the company: BD Mérieux
become BioMérieux.
1974
• Different acquisitions.
2004
Until
Now
• Listing of BioMérieux on the stock exchange.
• Different acquisitions.
Global presence
 BioMérieux = a part of the Institut Mérieux group
BioMérieux is present in 150 countries.
Global presence
 It has 17 production sites
Distributed in France, the Netherlands, the United Kingdom,
Italy, the United States, Brazil, Japan and Australia
A European logistics center located in France.
 Based in Marcy-l'Etoile, France
 Employs 6000 people worldwide, 880 people are
dedicated in bioMérieux, research, divided in 13 research
centers in the United States, Brazil and Europe (Lyon - France,
Florence - Italy, Boxtel - Country Netherlands).
BioMérieux : Some results in 2008
 8th Global Society in diagnostic biological
-
AC 1 111 million Euros
Realizes over 81% of its international business
Anonymous Society, capital = 12.029.370 €
Sales growth : + 9,8%
Cash flow : +19%
Status
• Anonymous society (AS) is a corporation so named
because his name does not reveal the names of
shareholders it may not even know the identity when the
company is on the stock exchange.
• Conventional Structure :
– A GD;
– A Board of Directors (11);
– General meetings.
Corporate Governance
• Board of Directors, Chairman : Alain Mérieux.
• Management Committee : 11
Alain Mérieux
Alexandre
Mérieux
CAPITAL
Stock-Market
• Stock exchange data :
– Number of shares : 39 453 740;
– Capitalization of stock-market : 3 223.77 MEUR;
– Activity sector : Medical equipment;

Share characteristics:
 Market: NYSE Euronext Paris;
 Stock symbol: BIM;

Average daily trading volume in 2008: approximately 34,700
shares => for a value of 2.3 million euros.
SHARE PRICE PERFORMANCE IN 2009
Acquisitions
1986
1988
2001
• Acquisition of API reference global identification and
manuals Antiobiogramme
• Acquisition of VITEK, American company
• Acquisition of Organon Teknika, diagnostic division of
Akzo Nobel
2006 : Sales by technology
Economic model
Very different business model from the
pharmaceutical industry.
1. Highly diversified product portfolio  less risk
• In sales : no blockbuster
• In the development pipeline
2. Shorter development cycles
3. No risk from generics
4. Lower product liability risk : In vitro vs In vivo
A promising market
The sentence
Strategy
• From a strategy focused on the
laboratory
Infectious diseases, oncology and
cardiology
Industrial applications
• To a strategy focused on pathologies and clinicians’ needs
Infectious agents : clinical and industrial applications
Tests delivering high medical value :
Oncology
Cardiology
Point-of-care tests
Theragnostics : therapeutics and diagnostics
Strategy Domain
Technologies
Growth
Pathologies
Industrial applications
Infectious diseases
Cancers
Cardio-vascular diseases
Diabet
Clinical chemistry
Endocrin Tests
Blood analysis
Auto-immun diseases
TDM/DOA tests **
Bacteriology
Molecular
Biology
Immunoassay
Clinical
Chemistry
Hematology
Hemostasis
2300
1800
8700
9100
1200
1200
3% - 4%
10% - 12%
3% - 4%
4% -5%
3% - 4%
3% - 4%
Low
Medium
High
High
Medium
Medium
Clinical applications
become a major reference for doctors and biologists on key
pathologies
Partnerships with pharmaceutical / biotech companies specialized in these
pathologies.
Cross-functional approach by pathologies
- One lead manager for each pathology
Bacteriology
Molecular biology
Immunoassays
Sepsis
Bact/Alert
GeneXpert
VIDAS PCT
Nosocomial infectious
PPM, VITEK 2
Diversilab
VIDAS CDA2
Tuberculosis
Bact/Alert
Gen-Probe
Infectious diseases
VIH/Hepatitis
easyMAG/EasyQ
VIDAS HIV
Cancers
VIDAS PSA
Cardio-vascular diseases
VIDAS D-dimers
Commercializing network
Commercializing on the quality of
commercial network
2007 – 2012 Growth rate*
• Internal R&D pipeline
• Sales network optimization
5-6%
1%
Optimization of commercial network
• Geographical priorities : United states and Japan
• Sustained creation of new subsidiaries :
 Algeria – 2007, South Africa – 2007,
 Singapore – 2008, Dubai - 2008
Etablishment of a global department
• Creating a world business management
Commercializing on the quality of
commercial network
• Pipeline after internal R&D
• Optimization of commercial
network
5-6%
1%
• Business Development
– Distribution agreement
– Acquisitions :
1-2%
• « Product companies »
• …
Total
7% - 9%*
* : Compound annual growth rate
Industry Control
Industry Control
leader sector consolidation
Aim : 2012  a market share of 30%
Industry - Strategy
Became the leader in industry consolidation
Aim
Internal growth
External growth
Assets
• 2012 : a market share of approx. 30 %
• PPM
• Develop an automated multi-target genetic
testing ( ADNA project )
• Agreements
• Acquisitions
• Undisputed Leadership
• Capitalizing on the clinical commercial
network
Partnerships
• Copan – 2007
– Exclusive worldwide distribution agreement authorizing bioMérieux to
market, for the pharmaceutical industry, an innovative sample collection
system based on technology developed by Copan.
– This patented product marks a major breakthrough because it is the first swab
on market that can be used to perform a quantitative environmental control.
The unique texture of the Nylon™ flocked swab picks up more microorganism
than conventional swabs. It is specifically designed for aseptic manufacturing
facilities control.
Acquisition for Industry
Acquisitions
2007
2008
BTF, Australia
To develop and market nextgeneration handheld diagnostic
solutions for « Point-of-Care »
PML microbiological, USA
BTF
• Provides the world's most precise quantitative reference standards
for microbiological testing .
• Use to verify the performance of control methods.
• Target customers in the industrial microbiology market, specifically
testing water, food and pharmaceutical products
• BTF’s range of products and expertise are a key addition to
portfolio of solutions for microbiological control
Infectious diseases expertise
Infectious diseases
Clinical diagnostic and industrial microbiology.
• Independence and expertise field
• International scope
• 45 years of experience and know-how
• Scientific and technological innovation
– 13% of the sales in R&D
– 3 main technologies
• Bacteriology
• Immunoassays
• Molecular biology
Strategic plan 2007/2012
• Bacteriology: “be an incontrovertible leader”
– Accelerate the complete automation of analysis processes
– Focus on chromogenic media
• Molecular biology: “become the key leader in sepsis and HAI”
– Be the leader of molecular diagnostic automation of HIV and hepatitis
– Biochips: launch of a multi-target genetic test PLC (ADNA project)
• Immunoassays: “increase the number of high-medical-value tests and
reinforce the Point of Care activity”
– VIDAS/VIDIA : extend the product range
– Patient’s Point of Care
• Based on the expertise in infectious diseases, technical mastery and on a
large number of products already on the market.
• Positioning : Full automation & Point of care in clinical market
Areas of Expertise
•
•
•
•
•
•
•
•
•
•
•
Healthcare Associated Infections
HIV
Sepsis
Tuberculosis
CNS infections
Gastro-intestinal infections
Hepatitis
Mother-to-child transmission
Urinary tract infections
Respiratory infections
Sexually transmitted infections




Products and strategy
• Improve the clinical presence (“Superbugs”, Theranostic …)
• Transverse approach regarding pathologies:
- One manager for each pathology
- One sponsor for each pathology in the executive committee
Partnerships with pharmaceuticals industries/biotechs working on those diseases.
Healthcare Associated Infections
•
•
•
•
Among the 10 leading causes of mortality in industrialized countries.
Impact on the length of hospitalization and related healthcare expenses.
5 billion$ annually in U.S. (WHO figures, 2005)
Affect around 10% of hospitalized patients, 1.4 million worldwide each day
Often characterized by resistance to antibiotics
•
bioMérieux research:
– New strains of drug-resistant bacteria: adding to collection of over 30,000 bacterial stains,
Centers for Disease Control (CDC)
– Automation: Full Microbiology Lab Automation, futher reducing time to result for bacterial
identification.
– Chromogenic media: direct, reliable and rapid isolation of bacteria
•
•
Prevention and surveillance: screening of patients, hospital environmental
controls, epidemiological surveillance.
Intervention: identification, antibiotic susceptibility testing, genotype
characterization, identify the source of infection and prevent epidemics.
Sepsis
•
•
•
•
•
Sepsis is the leading cause of death in non-coronary intensive care units.
Mortality from severe sepsis: 32 to 54%
In developed countries: estimation of 3,000 people die of severe sepsis a day.
In US, total cost of 16.7 billion dollars a year
Due to the aging of the population, invasive diagnostic techniques and increasing
bacterial resistance to antibiotics, the number of patients with sepsis is rising
steadily worldwide.
bioMérieux research: a race against the clock
– Tests easier to use, at the patient point’s of care
– Reduced time for the analysis of blood samples from several days to just 2hours
•
Diagnostic:
– Procalcitonin (PTC), introduced in VIDAS system.
•
•
20min to have early indications so the patient can be given adequate treatment
Same technology for monitoring antibiotic therapy and patient’s response to treatment
– Bacterial identification and antibiotic susceptibility testing: VITEK 2 system, Etest® (MIC)
– Automated blood culture: BacT/ALERT 3D, rapid growth and detection.
FMLA – Full Microbiology Lab Automation TM
To face challenges, automation =
 Standardization
 Speed
 Controlling healthcare costs
 Added value
- Inoculation of Petridishes: PREVI Isola™
- Automated staining of sample slides: PREVI™ Color Gram
- Urinary screening (detection of bacteria and particles): UF-1000i
- Blood culture: BacT/ALERT®
- Identification of bacteria and automated antibiogram: VITEK® 2
- Genotyping of microbialstrains: DiversiLab™
- VIDAS®
- NucliSENSEasyQ®
- NucliSENS® easyMAG®
A strategic partnership with
Hitachi High-Technologies
Corporation focused on
microbiology and molecular
5
diagnostics
Patient’s Point of Care
• Test performed and interpreted near the patient, by a
physician or a nurse.
• An estimatedmarket of $4b
– U.S. 65% of the market
– Averagegrowth rate 10% a year
• bioMérieux POC strategy
– Manualrapid tests
• QuickVue® tests: distribution agreement withQuidel (2008)
• Meikang Biotechrapid tests following acquisition (2010)
– Handheld diagnostic solution – Partnership with Philips (2013)
Results - Q4 2009
• Clinical field: 7,4% sales increase
– Extraction reagents (NucliSENS® easyMAG®) – H1N1 influenza
– Interest in FMLA (audit asked) especially PREVI Isola and PREVI Color Gram
– Immunoassays: VIDAS®, microplate screening, rapid testing
2009 Product Launches
• bioMérieux expanded its line of automated screening tests for
Methicillin Resistant Staphylococcus aureus (MRSA), one of the
leading causes of healthcare-associated infections
– In the US, chromID™ MRSA, chromogenic media that enables visual
identification of MRSA colonies in patient sample
– In Europe, NucliSENSEasyQ® MRSA, molecular diagnostic MRSA test
on the EasyQ® automated platform
– For both emergency and routine patient situations
• 17 new productswerebrought to marketduring the year:
–
–
–
–
NucliSENSEasyQ® HIV-1 v2.0, help FU of HIV positive patients
VIDAS® EBV, detection of EBV, 80% of infectious mononucleosis cases
VILINKTM, a secure network connection for VITEK®2 installations
VITEK®2 PC 4.02, software application compatible with European
antimicrobial susceptibility standards (EUCAST)
Bacteriology - strategy
Bacteriology - Strategy
Become the undisputed leader
Aim
• Accelerate the full automatisation of laboratory and
analysis process
• 2012 : market share of approx. 40%
Internal
growth
• PPM
• Blood culture : faster results thanks to new technologies
• Identification and antibiogram : menu extensions
External
growth
• Agreements
• Acquisitions
Assets
•More than 40 years of experience
•More than 50 % of the market in automated
bacteriology
Partnerships
• Cepheid - 2007
• The product menu comprises both bacterial and fungal identification assays as
well a series of genetic markers for antibiotic resistance.
– Cepheid is in charge of manufacturing
– bioMérieux distributes the sepsis assays
• LabTech Systems - 2007
– signed an exclusive worldwide license agreement for LabTech Systems’ automated
pre-poured media (PPM)  MicroStreak®.
• Eiken Chemical Co., Ltd. (Japan) - 2007
– Production of PPM for Biomérieux by Eiken Chemical Co.
• Sysmex (Japan) - 2008
– UF-1000i is highly standardized and automated solution for urinary screening
methods.
• Quidel (USA) – 2008
– Exclusive distributor of Rapid diagnosis test for Quidel. (Except USA, Japan and
Scandinavia)
Acquisitions for bacteriology
Acquisitions
2007
2008
Biomedics, Spanish
AB Biodisk, Swedish
A leader in Spain in the field of
bacteriology
expert in antibiotic susceptibility
testing in fastidious and unusual
organisms.
↗ production capabilities
for culture media
Commercialised
epsilometer test
Etest®
PML microbiological,
USA
In vitro diagnostics company
Acquisition of PML microbiological
 In vitro diagnostics company that provides culture media and
microbiological products for both clinical and industrial applications.
With this acquisition, bioMérieux is now :
USA
• one of the leading companies in the
field of microbiological control for the
pharmaceutical industry
Canada
• number one for the clinical culture
media in Canada.
Molecular biology
Molecular biology - Strategy
Become the leader in sepsis and hospital-acquired
infections
Aim
• Achieve a market share of 8%
Internal
growth
• Extend the NucliSens EasyQ platform menu
• Develop an automated multi-target genetic testing ( ADNA
project )
External
growth
• Agreements
• Acquisitions
Assets
• Expertise across the chain :
 extraction, amplification, detection
• Ability to capitalize on know-how in infections
Partnerships
• NuGEN Technologies Announce Cross-License and Supply Agreement.
(USA) - 2007
– NuGEN's exclusive WT-Ovation RNA Amplification System.
– enhances Biomérieux amplification capabilities for clinical use.
• AdvanDx (USA) - 2007
– To provide rapid results for Bloodstream results.
– identification of bacteria and yeast from positive blood cultures in less than three hours.
• Hitachi High-Technologies (Japan) – 2008
– R&D partnerships Focus on Microbiology and Molecular Diagnostics
Immunoassays
Immunoassays - Strategy
Extend the high medical-value test menu and
strengthen the point of care business
Aim
• VIDAS / VIDIA : strengthen the franchise
• Point of care : develop an manual and semiautomated range
Internal
growth
• VIDAS : optimize the installed base with new high
medical-value test
• VIDIA : develop tests for routine
• Point of care : introduction a rapid test reader
Assets
• Installed base of more than 20,000
instruments
• Expertise in antibodies
Partnerships and Acquisitions
2010
Partnerships
Acquisition
Philips
Chinese Rapid Test Manufacturer
Meikang Biotech
To develop and market nextgeneration handheld diagnostic
solutions for « Point-of-Care »
Reinforce bioMérieux’s position in the Pointof-Care and rapid test markets for both
emerging and deveped countries
China Strategy
bioMérieux in China today
• A long-standing presence
– Since 1978
– 1992: Hong Kong
– 2005: HQ moved to Shanghai
• 5 offices and more than 100 FTE
• A large distributor network
• A strategic foot hold in China
–
–
–
–
A large site and a strong team (mid-2010)
China becomes bioMérieux 3rd corporate pillar
Research team in Fudan University Cancer Hospital (Shanghai)
Joint-venture with Shanghai Kehua Bio-engineering (microplates)
• POC strategy : Manual rapid tests&Philips partnership
• Meikang Biotech acquisition; « this adds up »
MeikangBiotech
Activites synergy
• A well-establishedc ompany, Dr Chang - 1992
– 150 employees, 100 contractors
– Sales about €5M
– A wideproduct range: rapid tests
•
•
•
•
Infectious diseases
Carido-vascular and oncology
Drugs of abuse
Pregnancy and hormone testing
• A fully-owned manufacturing site in Shanghai
– 9,000m2 on 2 hectares of land
– 30 million tests per year
– Certifications: GMP, ISO 9001, ISO 13485,
Manufacturing license class III (Shanghai FDA)
MeikangBiotech
Higher ambitions for the Group
• Support business growth in China
– Rapid tests ideally complementing bioMérieux’s
product offering, mainly for infectious diseases
– In the coming years: additional production
capacities
• Optimize cost structure of products for
developing countries
• Leverage R&D expertise and develop innovative
products
– Additional immunoassay R&D capabilities for new
rapid tests
– A beachhead for the rapid diagnostics and POC
markets
Theranostics
Theranostic
The good drug for the good patient at the good time
A theranostic is a diagnostic test that helps
clinicians make the right therapeutic decision for
the right patients, enabling a more personalized
approach to medicine.
Theranostic
Theranostic
Microbiology
Oncology
« Le theragnostic devrait
déboucher sur un fort
développement commercial
après 2012 »
The Scientific need
• The overall five-year survival rate is still only 66%.
Causes for this high mortality rate include :
– late diagnosis
– challenging tumor identification and classification
– inappropriate treatment, all of which lead to poorer
patient outcomes
Partnerships - Cancer
• Leading Biotech for discovery and validation of molecular
biomarkers and proteomics,
• particularly for early detection and prediction of treatment
efficacy :
– ExonHit (France): breast, colon and prostate
– ProteoSys (Germany): prostate cancer
• Other partners contribute their expertise:
– French Atomic Energy Commission (CEA)
– the French National Scientific Research Center (CNRS)
– the Lyon University Hospitals (HCL)
– ST Microelectronics (ST)
– Claude Bernard University in Lyon (UCBL).
Biomarkers Development
Plan 2007 -> 2012
Theranostics: flexible way to
work
Gsk
Merck and Ipsen
Co-development of a
Co-development diagnostic predictive test with payers.
tests and the of new drugs Determine which treatment
Opportunity for label
integration and
co-marketing
is best suited to different
populations of patients
suffering from breast
cancer
Sept. 17, 2007. Patership in theragnostic development
• Co-funded The development of a companion test for BN83495;
intended for both :
– Clinical development of the compound
– Diagnostic test potentially for future commercialization
• The test will be developed on NucliSENS EasyQ®
molecular diagnostics platform. NASBA® amplification
technology.(CLIA certified laboratory)
• Tumour marker tests
– determining the molecular signature of tumours
– guiding a rational choice of treatment for defined patient groups.
The Target
• Novel breast cancer therapy
• designed to block the steroid sulfatase enzyme (STS).
sulfated steroid precursors
estrogens
STS
during pregnancy
• Found in hormone-dependent breast cancer in
postmenopausal women, but not BMI.
Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
Nakata T, Takashima S, Shiotsu Y, Murakata C, Ishida H, Akinaga S, Li PK, Sasano H, Suzuki T, Saeki T.
Pharmaceuticals Research and Development Division Kyowa Hakko Kogyo, Tokyo, Japan. taisuke.nakata@kyowa.co.jp
BN 83495 : Phase I
A first clinical study of Phase I
the results demonstrate the
inhibition of sulfatase enzyme
doses tested in tumor biopsies
A second phase I
Optimization dose of BN 83495 in
postmenopausal patients who
have an advanced breast cancer
hormone receptor positive.
Theranostics flexible way to
work
Merck and Ipsen
Co-development
diagnostic tests and the
of new drugs
Opportunity for label
integration and
co-marketing
Gsk
Co-development of a
predictive test.
Determine which
treatment is best suited
to different populations
of patients suffering
from breast cancer
Tyverb, lapatinib
• Lapatinib is an oral small-molecule
• inhibitor of the ErbB2/ ErbB1 TK receptor.
Trastuzumab
Lapatinib
Tyverb, lapatinib
• Develop in breast cancer
• Over expression of these receptors has been reported in a
variety of human tumors.(squamous cell/gastric cancer)
• Associated with poor prognosis and reduced overall
survival.(agresive form of advanced breast cancer)
•
•
•
•
•
Limits
Not in Monotherapy
Poso: 5 tablets/ day, every days
2174€ / month
2 x 70 tablets = 2537,74 €
Adverse reactions, at least 10% of patients (Gastrointestinal, dermatologic, fatigue…)
Approval and funded
Lapatinib received approval in june 2008
FDA - EMEA
• 1st indication: In combination with Xeloda (growth inhibitor) for a
particular type of aggresive breast cancer : ErbB2+. After treatment with
standard chemotherapy regimes including intravenous trastuzumab
• 2nd indication in combination with letrozole (aromatase inhibitor) for the
first-line treatment of HER2-positive metastatic breast cancer in
postmenopausal women.
FDA
• 3thr indication in combination with letrozole (aromatase inhibitor) for the
first-line treatment of HER2-positive metastatic breast cancer .
• Refusal to pay for lapatinib as a 1st-line and 2nd-line treatment for HER2positive breast cancer (EGF 30008)
=>finding it was not cost-effective.
Cost-effectiveness
• Analysis lapatinib + capecitabine vs capecitabine
monotherapy
• the QALY gain was 0.171 at an incremental cost of
£13,873
• Incremental cost-effectiveness ratio (ICER) of
£81,251 per QALY gained. Max £35,000
• the cost effectiveness of lapatinib was particularly
influenced by the extent of trastuzumab use post
progression and the progression free patients
receiving trastuzumab.
COMMISSION DE LA
TRANSPARENCE
Avis 16 juillet 2008
• L’EMEA a attribué à TYVERB une AMM conditionnelle, en
l’absence :
- de données robustes sur l’efficacité de TYVERB sur
l’incidence des métastases cérébrales
- et de démonstration sur la survie globale.
• Le rapport bénéfice/risque sera réévalué annuellement. La
firme s’est engagée auprès de l’EMEA :
- données de survie : étude EGF 100 151
- phase III comparative vs HERCEPTIN
Evaluer l’effet de TYVERB sur l’incidence des métastases
cérébrales =site de rechute (Le rapport final soumis en mai
2013).
November 17, 2009
• Development of a predictive test => treatment best
suited to different populations suffering from breast
cancer.
• ”This test will be developed from new biomarkers.
After approval by regulatory agencies, it can be used
for both cancer receiving adjuvant therapy and
metastatic cancer”
• Test ErbB2 / ErbB1 ???
• GSK did not reveal the specific breast cancer drugs that
the predictive test would accompany.
Oncology pipeline
• GSK's decision to work with BioMerieux:
capacity to scale up the development and
marketing of the test. (not only a biotech)
• GSK : Opportunity for label integration and
co-marketing
AviaraDx acquisition
En septembre 2008
le Groupe a acquis la société AviaraDx, Inc. spécialisée en
diagnostic moléculaire des tissus tumoraux à partir de
biopsies.
Accrédité par un CAP
THEROS Breast Cancer IndexSM
Breast cancer recurrence
• Breast cancer patients are typically classified by 3 factors
• 40% to 50% percent of breast cancer patients are
inaccurately classified as “intermediate risk” according
to St. Gallen’s risk assessment guidelines.
– under-treated=> overall survival
– over-treated=> cost, side effect
low
intermediate
high-risk
• Better classification means better treatment selection
• Test is a combination of 2 independent tests:
– ER and PR , endocrine therapy.
– Tumors ,be sensitive or resistant to chemotherapy.
THEROS technology
• THEROS Breast Cancer ℠ and THEROS CancerTYPE ID®
–
–
–
–
–
–
–
objective diagnostic tool
quantifiable
Practical
clinically impactful.
faster,
effective
avoid expensive
• real time RT-PCR based assays compatible with many form
of samples.
– extraction of RNA
– reverse transcription to cDNA
– quantitative measurement using real time PCR
THEROS CancerTYPE ID®
1.4 million new cases ofcancer in the US, 3 to 5% of new cancer are « cancer
of unknown primary »; Diagnotisis:
-lengthy
-expensive: $18,000*
•Diagnostic tools used studying cells and tumors with microscopes, laboratory cell
stains , imaging
•often fall short of identifying where a cancer started and what type it is.
•Molecular diagnostics provides important information for cancer type
identification
•The price of a Cancer type test is 3600$
•Recognize over 75% of solid tumors. activity levels of 92 genes
distinguish up to 39 different tumor types and 64 subtypes
*Schapira DV, Jarrett AR. The need to consider survival, outcome, and expense when evaluating and treating patients with
unknown primary carcinoma. Arch Inter Med.;155:2050-2054, 1995.
• SAN DIEGO Breast Cancer Symposium
December 12, 2009
three studies using the company’s breast
cancer molecular test (leader d’opinions)
http://www.biotheranostics.com/wp-content/uploads/Test-Requisition-Form-website.pdf
a two-year agreement with Lab21 to commercialize the bioTheranostics THEROS CancerTYPE ID
Conclusion
Clear objectives
• a strategy focused on patients and pathologies
– Infectious agents : clinical and industrial applications
– high medical-value tests : oncology, cardiology, point of care and
theragnostics
• Strategy that leverages their strenghs
– Bacteriology : leadership
– Industry : lead sector consolidation
– Molecular biology : become the leader on sepsis and hospital-acquired
infections
– Immunoassays : extend the high medical-value test menu and
strengthen the point of care business
– Theranostics : become a preferred partner for pharmaceutical and
biotech compagnies
Good financial results
for the third quarter
Sysmex :
Biomerieux
become Sysmex’s
global partner for
distributing
UF1000i
Acquisition of BTF
Institut Mérieux
sells Laboratoire
Marcel Mérieux
shares its CEO
Cepheid :
Relationship in the
development
and
commercialization of
an innovative line of
sepsis test products
AviaraDx
acquisition +
Bad financial
results in USA1
Flu threat
SWOT
Future Acquisitions ?
• Biomonitor ?
– Danish biotechnology company leader in thenostics and
combine development of innovative and proprietary clinical
bioassays.
– Products : iLite™  Products based upon the « gene reporter »
technology.
• Exonhit ?
– A world leader in the exploitation of alternative RNA splicing.
– Is ability to identify genes whose splice variants produce
abnormal proteins can be used to develop tests for diagnosing
diseases at an early stage.
Conclusion
Conclusion
Who wants to work at bioMérieux
Name
Opinion
Alban
+++
Emmanuel
+++
Thibaut
+++
Thomas
+++